Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: financial performance shows improvement with reduced losses and expenses, yet funding challenges and macroeconomic conditions pose risks. Despite positive regulatory guidance and potential partnerships, the lack of specific feedback from the medical community and operational cost concerns temper optimism. The neutral sentiment reflects these balanced factors, with no clear catalyst for a strong price movement.
Key Financial Performance
Cash Balance $6.1 million as of June 30, 2025, compared to $3.7 million as of December 31, 2024, an increase due to raising approximately $3.4 million of gross proceeds through purchases under the equity line of credit and a Warrant Inducement agreement.
Research and Development Expenses (3 months ended June 30) $0.5 million in 2025 compared to $1.8 million in 2024, a decrease of $1.3 million primarily due to a $0.3 million decrease in manufacturing costs and a $1 million decrease in consulting costs as a result of prior year trial-related expenses.
Research and Development Expenses (6 months ended June 30) $1.1 million in 2025 versus $3.4 million in 2024, a decrease of $2.3 million primarily due to a $0.6 million reduction in manufacturing costs and a $1.7 million decrease in consulting costs due to higher trial-related costs in the prior year.
General and Administrative Expenses (3 months ended June 30) $1.7 million in 2025 compared to $2.3 million in 2024, a decrease of $0.6 million primarily due to a $0.7 million decrease in share-based compensation, offset by a $0.1 million increase in professional fees.
General and Administrative Expenses (6 months ended June 30) $3.3 million in 2025 versus $5.1 million in 2024, a decrease of $1.8 million due primarily to a $0.6 million decrease in professional fees and a $1.2 million decrease in share-based compensation.
Net Loss (3 months ended June 30) $2.2 million or $1.89 per diluted share in 2025 compared to $4.1 million or $5.21 per diluted share in 2024, a decrease due to reduced research and development and general and administrative expenses.
Net Loss (6 months ended June 30) $4.4 million or $4.01 per diluted share in 2025 compared to $8.5 million or $10.84 per diluted share in 2024, a decrease due to reduced research and development and general and administrative expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Patent Granted: The Indian Patent Office granted a new patent for DNA polymerase IIIC inhibitors, expiring in December 2039, supporting the preclinical antibiotic development program of ACX-375C.
Phase IIb Clinical Trial Data: Published in Lancet Microbe, ibezapolstat showed high clinical cure rates, no recurrence, and preservation of healthy gut bacteria, positioning it as a novel treatment for C. difficile infection.
FDA Designations: Ibezapolstat has FDA QIDP and Fast Track designations for treating C. difficile infection.
Market Need for Ibezapolstat: Ibezapolstat addresses a critical need for new antibiotics to treat C. difficile infection, which has a $5 billion annual U.S. cost burden, including $2.8 billion due to recurrent infections.
Funding Activities: Closed an equity line of credit for $12 million and raised $2.7 million through warrant inducement agreements, with net proceeds of $2.5 million.
Cost Reductions: R&D expenses decreased by $1.3 million in Q2 2025 compared to Q2 2024, and G&A expenses decreased by $0.6 million in the same period.
Reverse Stock Split: Implemented a 1-for-20 reverse stock split to comply with NASDAQ listing requirements.
Collaboration with Leiden University: Presented data on the mechanism of action of polymerase IIIC inhibitors at a scientific conference, highlighting its potential against Gram-positive pathogens.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Funding Challenges: The company is actively pursuing multiple funding opportunities, including equity lines of credit, warrant inducements, and public-private partnerships, to support its Phase III clinical trial program for ibezapolstat. This indicates potential financial constraints and reliance on external funding to sustain operations and strategic objectives.
Regulatory Compliance: The company implemented a 1-for-20 reverse stock split to comply with NASDAQ listing maintenance requirements, highlighting challenges in meeting regulatory and listing standards.
Macroeconomic Environment: The company acknowledges navigating through challenging macroeconomic conditions, which could impact its operations and financial performance.
Antimicrobial Resistance: Emerging antimicrobial resistance to existing CDI treatments underscores the need for new antibiotics like ibezapolstat. However, this also presents a challenge in terms of ensuring the efficacy and market acceptance of new treatments.
Operational Costs: The company reported a decrease in research and development expenses and general administrative expenses compared to the previous year, which may reflect cost-cutting measures but could also impact the pace of development and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future Funding and Capital Raising: The company will continue its multistep approach to raising capital through customary financings, warrant inducements, and public-private partnership opportunities.
Phase III Clinical Trial Program for Ibezapolstat: The company is actively identifying and pursuing funding opportunities for its Phase III clinical trial program for ibezapolstat and considering alternative financial pathways to achieve success.
Ibezapolstat's Market Potential: Ibezapolstat, if approved, could reduce the overall annual U.S. cost burden for C. difficile infection, which is approximately $5 billion a year, with $2.8 billion attributed to recurrent infection.
Regulatory Designations for Ibezapolstat: Ibezapolstat has FDA QIDP and Fast Track designations for the treatment of CDI, which underscores its potential as a novel antibiotic treatment.
Macroeconomic and Industry Challenges: The company remains confident in navigating challenging macroeconomic and industry conditions while continuing to strengthen ibezapolstat's competitive profile.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Is the trend of operating expenses coming down expected to continue through 2025 and 2026?
A:Yes, the company is trimming expenses significantly. The cash burn is down to close to $400,000 a month, and this trend is expected to continue. There are plans for a small clinical trial that will be financially manageable, with more details to be announced next quarter.
Q:When should we anticipate a partnership or government collaboration for ibeza?
A:A partnership could be announced anytime in the second half of the year. Government collaborations are ongoing and may extend into 2026 due to funding dynamics in Washington. The federal government's fiscal year-end is September 30, and funding for the new fiscal year is expected to be appropriated by year-end.
Q:What feedback has been received from the physician or KOL community on the publication of the IIb data?
A:No specific feedback from the physician or KOL community was mentioned in the response.
Q:Are there any rate-limiting steps ahead of the upcoming Phase III studies?
A:The only minor rate-limiting step is the fill/finish of the ibezapolstat supply for the Phase III trials. This process may take a couple of months but is not significant. The European Medicines Agency and FDA have agreed on the same protocol for the trials, which is a positive development.
Q:Review of Unclear Management Responses
A:The response to the question about feedback from the physician or KOL community on the IIb data publication lacked specific details or examples of feedback received.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Acurx
Co Founder
Conference
Leiden University
Medical Center
PhD
Professor
Research Division
Series warrant
University Medical
aggregate share
agreement
author
decrease trial
equity line
exercise price
exercise warrant
fidaxomicin
line credit
polymerase IIIC
price share
publication
rate cure
share Series
share stock
split
stock exercise
stock share
stock term
treatment CDI
treatment guideline
warrant aggregate
warrant inducement
warrant share
ACXP Transcript
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call highlights significant progress in clinical trials, a favorable FDA one-trial requirement, and an extended patent, all potentially reducing time to market and enhancing IP protection. Financials show reduced losses and prudent expense management. The Q&A reinforces confidence in trial strategies and FDA alignment. Although macroeconomic challenges exist, the overall sentiment is positive, suggesting a potential stock price increase in the short term, especially if the market recognizes the strategic advancements and financial discipline.
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call Transcript
Unknown3-13
The earnings call presents a mixed picture: significant cost reductions and decreased net losses are positive, but there's uncertainty in trial timelines and management's vague responses in the Q&A. While financial health has improved, the lack of clear guidance and potential delays in trials temper optimism. The absence of a market cap makes it difficult to gauge stock volatility, suggesting a neutral sentiment with a potential slight positive shift if trial developments progress smoothly.
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript
Unknown11-12
The earnings call reveals both positive and negative aspects. On the positive side, there are significant cost reductions and potential regulatory advantages for ibezapolstat, supported by FDA designations. However, the company faces financial sustainability issues, with ongoing net losses and uncertainties in partnership timelines. The Q&A section showed management's cautious optimism but lacked concrete timelines or commitments, which could dampen investor confidence. Given these mixed signals, the stock is likely to remain stable in the short term, resulting in a neutral market reaction.
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call Transcript
Unknown8-12
The earnings call presents a mixed picture: financial performance shows improvement with reduced losses and expenses, yet funding challenges and macroeconomic conditions pose risks. Despite positive regulatory guidance and potential partnerships, the lack of specific feedback from the medical community and operational cost concerns temper optimism. The neutral sentiment reflects these balanced factors, with no clear catalyst for a strong price movement.
ACXP Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
